Kiin Bio Revolutionizes Drug Discovery with $1.6m Pre-Seed Funding

Deal News | Jun 05, 2025 | UK Tech Funding

Kiin Bio Revolutionizes Drug Discovery with $1.6m Pre-Seed Funding

Kiin Bio, a London-based startup, has raised $1.6 million in pre-seed funding to develop a generative AI-driven drug discovery platform. The company aims to revolutionize drug discovery by creating a cohesive AI-native infrastructure that brings together fragmented solutions into a Virtual Scientist Platform. This innovative approach is aimed at integrating automated technologies into the expensive and fragmented drug discovery market, projected to generate up to $110 billion annually. Prominent investors, including b2venture, Heartfelt, rule30, and several angels, have backed this pioneering enterprise. The goal of Kiin Bio's platform is to transform the way drug discovery is conducted by turning disparate tools and data into a unified engine for scientific breakthroughs. According to Filippo Abbondanza, CEO and co-founder, the platform promises smarter integration for more efficient drug development.

Sectors

  • Biotechnology
  • Artificial Intelligence
  • Venture Capital

Geography

  • United Kingdom – Kiin Bio is a London-based startup, emphasizing the UK's role in fostering innovation in the AI and biotech industries.

Industry

  • Biotechnology – Kiin Bio operates within the biotechnology industry, focusing on drug discovery through AI technologies.
  • Artificial Intelligence – The article highlights the use of generative AI in Kiin Bio’s drug discovery efforts, making AI an integral part of their operations.
  • Venture Capital – The participation of investors such as b2venture and others indicates involvement in venture capital activities, focusing on funding innovative startups.

Financials

  • 1.6 million – The pre-seed funding amount secured by Kiin Bio to launch its drug discovery platform.
  • 110 billion – The projected annual value of the generative AI drug discovery market.

Participants

NameRoleTypeDescription
Kiin BioTargetCompanyA startup developing an AI-driven drug discovery platform.
b2ventureLead InvestorCompanyA venture capital firm leading the investment round in Kiin Bio.
HeartfeltInvestorCompanyParticipated in the pre-seed funding round.
rule30InvestorCompanyParticipated in the pre-seed funding round.
Filippo AbbondanzaCEO and Co-founderPersonChief executive and co-founder of Kiin Bio, focusing on AI-driven drug discovery.
Andreas GoeldiPartner at b2venturePersonPartner at b2venture, advocating for investment in Kiin Bio's transformative drug discovery approach.